Get started
Author

Heena Mavani

Impact of ibrutinib dose adjustment on TTNT in first-line CLL/SLL: a real-world analysis using target trial emulation
2024 · Nilanjan Ghosh, Ruibin Wang, et al. · Blood Neoplasia · 7
Comparative Effectiveness of Ibrutinib Flexible Dosing Treatment Strategies on Time to Next Treatment in a Largely Community-Based Claims Database: A Target Trial Emulation Study
2023 · Nilanjan Ghosh, Ruibin Wang, et al. · Blood · 7
Real-world (RW) dosing patterns and outcomes among chronic lymphocytic leukemia (CLL) patients (pts) with or without an ibrutinib (IBR) dose adjustment (DA) in first-line (1L).
2023 · Kerry Anne Rogers, Xiaoxiao Lu, et al. · Journal of Clinical Oncology · 7
Oncology's Trojan Horse: Using Viruses to Battle Cancer
2016 · HeenaJ. Mavani, JeannetteY. Wick · The Consultant Pharmacist · 7
Ibrutinib Dose Adjustment Does Not Impact Time to Next Treatment in First-Line Patients with Chronic Lymphocytic Leukemia: A Real-World Analysis of Electronic Medical Records from Academic and Non-Teaching Hospitals Using Target Trial Emulation
2023 · Nilanjan Ghosh, Zaina P Qureshi, et al. · Blood · 5
CLL-585 Real-World Assessment of Dosing Patterns and Treatment Outcomes in Patients With Chronic Lymphocytic Leukemia Who Initiated First-Line Single-Agent Ibrutinib in an Integrated Claims-Based Database
2023 · Nilanjan Ghosh, Ruibin Wang, et al. · Clinical Lymphoma Myeloma & Leukemia · 2
PDF
Ibrutinib oral suspension bioavailability and compatibility for optimal enteral administration route
2025 · Jonas Paludo, Lisa Nodzon, et al. · Therapeutic Advances in Hematology · 1
Real-world treatment outcomes in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma who were treated with first-line single-agent ibrutinib vs. chemoimmunotherapy.
2023 · Ruibin Wang, Zhijie Ding, et al. · Journal of Clinical Oncology · 1
CO102 Physician Reported Treatment Attributes Considered in First-Line and Perceptions Around Bruton Tyrosine Kinase Inhibitor (BTKi) Treatments in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) in the US
2023 · C. Jensen, Z. Ding, et al. · Value in Health
PDF
POSTER: CLL-586 Real-World Dosing Patterns and Outcomes Among Patients With Chronic Lymphocytic Leukemia With or Without Dose Adjustment of First-Line Ibrutinib
2023 · Kerry Rogers, Xiaoxiao Lu, et al. · Clinical Lymphoma Myeloma & Leukemia
POSTER: CLL-587 Real-World Treatment Outcomes in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Who Were Treated With First-Line Single-Agent Ibrutinib vs Chemoimmunotherapy
2023 · Ruibin Wang, Zhijie Ding, et al. · Clinical Lymphoma Myeloma & Leukemia
PDF
CLL-587 Real-World Treatment Outcomes in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Who Were Treated With First-Line Single-Agent Ibrutinib vs Chemoimmunotherapy
2023 · Ruibin Wang, Zhijie Ding, et al. · Clinical Lymphoma Myeloma & Leukemia
PDF
CLL-586 Real-World Dosing Patterns and Outcomes Among Patients With Chronic Lymphocytic Leukemia With or Without Dose Adjustment of First-Line Ibrutinib
2023 · Kerry Rogers, Xiaoxiao Lu, et al. · Clinical Lymphoma Myeloma & Leukemia
POSTER: CLL-585 Real-World Assessment of Dosing Patterns and Treatment Outcomes in Patients With Chronic Lymphocytic Leukemia Who Initiated First-Line Single-Agent Ibrutinib in an Integrated Claims-Based Database
2023 · Nilanjan Ghosh, Ruibin Wang, et al. · Clinical Lymphoma Myeloma & Leukemia
Works count: 14
Citation count: 37
H-index: 5
I10-index:
Year
Topic
Type